Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing targeted therapies for people of all ages living with life-threatening diseases, with an initial focus on pediatric and rare cancers. Its lead product OJEMDA (tovorafenib) is an FDA-approved treatment for relapsed or refractory pediatric low-grade glioma, and its pipeline includes DAY301 and the antibody-drug conjugate Emi-Le. Headquartered in Brisbane, California, the company was acquired by and is now part of the Servier Group as of March 2026. Day One was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network; it maintains a corporate and investor-relations web presence but publishes no public developer API, SDK, or programmatic surface.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Day One Biopharmaceuticals the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Day One Biopharmaceuticals scores 14.6/100 (minimal), with a separate agent-readiness read of 4/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Day One Biopharmaceuticals
Each block below is one kind of artifact we hold for Day One Biopharmaceuticals. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Day One Biopharmaceuticals — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/day-one-biopharmaceuticals · machine-readable index on apis.io